The FDA recently approved insulin glulisine [DNA origin](Apidra, Aventis Pharmaceuticals) for the control of hyperglycemia in adult patients with diabetes mellitus. According to the manufacturer, insulin glulisine should be used in regimens that include a longer-acting insulin or basal insulin analog. Aventis recently announced that it will delay the launch of insulin glulisine until after the approval of its OptiClick pen delivery device
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.